tiprankstipranks
Trending News
More News >
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
US Market

Enliven Therapeutics (ELVN) AI Stock Analysis

Compare
293 Followers

Top Page

EL

Enliven Therapeutics

(NASDAQ:ELVN)

Rating:36Underperform
Price Target:
Enliven Therapeutics' stock is challenged by its early-stage financial profile with no revenue and ongoing losses. Despite strong liquidity, the reliance on external financing and lack of profitability weigh heavily. Technical indicators reinforce a cautious approach, as the stock shows bearish trends. Valuation metrics further reflect the typical risk profile of a biotech company in development.
Positive Factors
Efficacy and Safety
ELVN-001 has shown a clean safety profile with low rates of adverse effects, dose reductions, and discontinuations.
Financial Position
Enliven strengthened their financial position by raising significant funds, ensuring financial stability through pivotal data milestones.
Market Opportunity
There is a significant market opportunity for ELVN-001, with a large patient population in the 2L+ and 3L+ CML settings.
Negative Factors
Adverse Events
16.1% of patients had dose interruptions, 3.4% had dose reductions, and 4.6% discontinued treatment due to a treatment-emergent adverse event.
Safety Concerns
There are no notable safety concerns observed, with only 10% of patients experiencing Grade ≥3 treatment-related adverse effects.

Enliven Therapeutics (ELVN) vs. SPDR S&P 500 ETF (SPY)

Enliven Therapeutics Business Overview & Revenue Model

Company DescriptionEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
How the Company Makes MoneyEnliven Therapeutics makes money primarily through the development and commercialization of its proprietary therapeutic products. The company's revenue model includes securing funding through partnerships with larger pharmaceutical companies, licensing agreements, and potential milestone payments as their drug candidates progress through clinical trials. Once a therapeutic product receives regulatory approval, Enliven Therapeutics generates revenue through product sales, either directly or via distribution agreements with strategic partners. Additionally, the company may engage in collaborations for research and development, which can provide upfront payments and ongoing royalties based on sales performance.

Enliven Therapeutics Financial Statement Overview

Summary
Enliven Therapeutics is in the early development stage typical of biotech firms, characterized by a lack of revenue and financial losses. While strong liquidity supports operations, the company remains dependent on external financing. Recent improvements in financial stability are notable, but profitability challenges persist.
Income Statement
15
Very Negative
Enliven Therapeutics has shown a consistent pattern of negative revenue, gross profit, and net income, indicating significant challenges in generating sales and managing costs. The lack of revenue growth and persistent losses highlight the company's early-stage nature in the biotechnology sector, where long development cycles are common.
Balance Sheet
40
Negative
The balance sheet reflects strong liquidity with substantial cash reserves and no debt, supporting operational needs. However, negative stockholders' equity in previous years and current low total liabilities suggest potential financial instability. The company's equity ratio has improved recently, indicating better capital management.
Cash Flow
35
Negative
Cash flow statements indicate negative operating cash flows and free cash flows, which is typical for a biotechnology firm in the development phase. The company has maintained substantial financing activities, reflecting reliance on external capital to support operations. The operating cash flow to net income ratio is below optimal levels, underscoring challenges in converting income to cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-79.00K-317.00K-297.00K-622.00K-99.00K-97.00K
EBITDA-110.02M-88.47M-81.93M-38.58M-24.65M-9.27M
Net Income-94.83M-89.02M-71.58M-37.75M-24.72M-18.93M
Balance Sheet
Total Assets302.57M325.76M271.87M83.30M113.33M131.00M
Cash, Cash Equivalents and Short-Term Investments289.56M313.44M253.15M75.54M110.02M130.37M
Total Debt0.000.00335.00K323.00K159.00K105.00K
Total Liabilities14.27M15.91M25.96M160.12M156.22M151.31M
Stockholders Equity288.30M309.85M245.91M-76.83M-42.89M-20.30M
Cash Flow
Free Cash Flow-74.00M-73.24M-61.42M-32.69M-19.32M-8.99M
Operating Cash Flow-73.96M-73.19M-61.27M-32.08M-19.13M-8.53M
Investing Cash Flow-68.23M-36.00M-148.41M-612.00K-191.00K-461.00K
Financing Cash Flow43.13M133.16M234.29M-1.80M-1.02M130.51M

Enliven Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price19.65
Price Trends
50DMA
19.35
Positive
100DMA
19.73
Negative
200DMA
22.23
Negative
Market Momentum
MACD
0.37
Positive
RSI
46.73
Neutral
STOCH
8.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELVN, the sentiment is Negative. The current price of 19.65 is below the 20-day moving average (MA) of 21.10, above the 50-day MA of 19.35, and below the 200-day MA of 22.23, indicating a neutral trend. The MACD of 0.37 indicates Positive momentum. The RSI at 46.73 is Neutral, neither overbought nor oversold. The STOCH value of 8.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELVN.

Enliven Therapeutics Risk Analysis

Enliven Therapeutics disclosed 89 risk factors in its most recent earnings report. Enliven Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Enliven Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$1.02B-57.92%-13.37%2.57%
57
Neutral
$933.10M-36.26%127.33%21.31%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
45
Neutral
$878.95M-45.35%22264.23%39.09%
44
Neutral
$998.34M-77.86%-1.00%
43
Neutral
$934.88M2.31-50.47%-100.00%94.68%
36
Underperform
$1.16B-31.30%12.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ELVN
Enliven Therapeutics
20.64
-1.78
-7.94%
GERN
Geron
1.40
-3.13
-69.09%
ARDX
Ardelyx
4.19
-1.10
-20.79%
SYRE
Spyre Therapeutics
15.50
-9.99
-39.19%
NTLA
Intellia Therapeutics
10.73
-12.03
-52.86%
PLSE
Pulse Biosciences
15.32
3.27
27.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025